Board Changes
02/05/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230502:nRSB9350Xa&default-theme=true
RNS Number : 9350X Accrol Group Holdings PLC 02 May 2023
2 May 2023
Accrol Group Holdings plc
("Accrol, the "Group" or the "Company")
(AIM: ACRL)
Board Changes
Appointment of new Chief Financial Officer
Accrol, the UK's leading independent tissue converter, is pleased to announce
that Chris Welsh has today joined the Board as Chief Financial Officer
("CFO").
As detailed in the HY23 Results announcement, Chris succeeds Richard Newman,
who has now resigned as CFO and stepped down from the Board but, to ensure a
smooth transition, has agreed to remain with the Company until the FY23 audit
process is completed and the Final Results are released.
Chris joined the business in October 2022, as part of the Board's succession
planning. Before his move to Accrol, Chris held several senior finance roles
at the multinational chemical manufacturing group, Ineos, most latterly as
Head of Financial Reporting at the Enterprises Division.
Chris is a Chartered Accountant, who qualified with PwC in 2015.
Gareth Jenkins, Chief Executive Officer, said:
"We are delighted to welcome Chris to the Board. Since joining Accrol last
year, he has been operating at the highest standard, demonstrating the
commitment, energy and acumen which will help deliver our strategic
objectives.
"I would also like to take this opportunity to thank Richard for his
significant contribution to the Group. On appointment, he was tasked with
transforming the finance function of the business, which he has achieved.
Richard hands over to Chris a much strengthened finance team and
infrastructure, capable of serving a much larger business."
Further information relating to Christopher Welsh
In accordance with Schedule 2(g) of the AIM rules, Christopher ("Chris") James
Welsh (aged 33) holds or has held in the past five years the following
directorships:
Current directorships
· Accrol UK Limited
· LTC Parent Ltd
· John Dale Holdings Limited
· Leicester Tissue Company Limited
· Art Tissue Ltd
· Accrol Papers Limited
· Accrol Holdings Limited
· John Dale Limited
Chris holds no shares in the Company.
There is no further information on Chris required to be disclosed under
Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies.
For further information, please contact:
Accrol Group Holdings plc
Dan Wright, Executive Chairman Via Belvedere Communications
Gareth Jenkins, Chief Executive Officer
Chris Welsh, Chief Financial Officer
Zeus (Nominated Adviser & Broker)
Dan Bate / Jordan Warburton Tel: +44 (0) 161 831 1512
Dominic King Tel: +44 (0) 203 829 5000
Shore Capital Stockbrokers (Joint Broker) Tel: +44 (0) 20 7408 4090
Malachy McEntyre / Mark Percy / James Thomas
Belvedere Communications Limited
Cat Valentine Tel: +44 (0) 7715 769 078
Keeley Clarke Tel: +44 (0) 7967 816 525
accrolpr@belvederepr.com
Overview of Accrol
Accrol Group Holdings plc is a leading tissue converter and supplier of toilet
tissues, kitchen rolls, facial tissues, and wet wipes to many of the UK's
leading discounters and grocery retailers across the UK. The Group now
operates from six manufacturing sites, including four in Lancashire, which
together supply c.21.5% (volume) of the UK tissue market valued at c£2.5bn at
retail sales value.
For more information, please visit www.accrol.co.uk
(http://www.accrol.co.uk/) .
Link for Accrol Today video: https://www.accrol.co.uk/our-business/
(https://www.accrol.co.uk/our-business/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BOAUWOSROSUSUAR